Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases

Jean E Vance, Jean E Vance

Abstract

Dysregulation of cholesterol homeostasis in the brain is increasingly being linked to chronic neurodegenerative disorders, including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), Niemann-Pick type C (NPC) disease and Smith-Lemli Opitz syndrome (SLOS). However, the molecular mechanisms underlying the correlation between altered cholesterol metabolism and the neurological deficits are, for the most part, not clear. NPC disease and SLOS are caused by mutations in genes involved in the biosynthesis or intracellular trafficking of cholesterol, respectively. However, the types of neurological impairments, and the areas of the brain that are most affected, differ between these diseases. Some, but not all, studies indicate that high levels of plasma cholesterol correlate with increased risk of developing AD. Moreover, inheritance of the E4 isoform of apolipoprotein E (APOE), a cholesterol-carrying protein, markedly increases the risk of developing AD. Whether or not treatment of AD with statins is beneficial remains controversial, and any benefit of statin treatment might be due to anti-inflammatory properties of the drug. Cholesterol balance is also altered in HD and PD, although no causal link between dysregulated cholesterol homeostasis and neurodegeneration has been established. Some important considerations for treatment of neurodegenerative diseases are the impermeability of the blood-brain barrier to many therapeutic agents and difficulties in reversing brain damage that has already occurred. This article focuses on how cholesterol balance in the brain is altered in several neurodegenerative diseases, and discusses some commonalities and differences among the diseases.

Figures

Fig. 1.
Fig. 1.
Cholesterol biosynthesis. Cholesterol is synthesized from acetyl-CoA. A key intermediate in the pathway, mevalonic acid, is produced from 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by the rate-limiting enzyme of the pathway, HMG-CoA reductase; this enzyme is inhibited by the cholesterol-lowering drugs, the statins. In the final step of the pathway, 7-dehydrocholesterol is converted to cholesterol by the enzyme 7-dehydrocholesterol reductase, the defective enzyme in SLOS. Hydroxylated derivatives of cholesterol, such as 24-, 25- and 27-hydroxycholesterol, are produced from cholesterol by specific hydroxylases, such as CYP46.
Fig. 2.
Fig. 2.
APOE-containing lipoproteins transport cholesterol from astrocytes to neurons. Glial cells, primarily astrocytes, but also microglia, secrete APOE, which acquires cholesterol and phospholipids, thereby forming APOE-containing lipoproteins. These are delivered to neurons where they are endocytosed via cell surface receptors (members of the LDL receptor family). Consequently, cholesterol is delivered to the neurons. Some APOE receptors also function as signaling receptors.
Fig. 3.
Fig. 3.
NPC1 and NPC2 mediate cholesterol export from late endosomes and/or lysosomes. Cholesterol (blue oval) is released from endocytosed LDLs and binds to NPC2 (red), a soluble protein in the lysosomal lumen. Subsequently, NPC2 directly transfers the cholesterol to NPC1 (yellow), located in the limiting membrane of the lysosome, so that the hydrophobic cholesterol molecule does not have to travel through the aqueous milieu of the lysosomal lumen. Ultimately, the cholesterol is exported from the lysosomal membrane and is transported via the cytosol to the endoplasmic reticulum and plasma membrane by unknown mechanisms.
Fig. 4.
Fig. 4.
Processing of APP. In the non-amyloidogenic pathway of APP processing, APP is proteolytically cleaved within the Aβ region (red box) by α-secretase (α). In the amyloidogenic pathway, APP is cleaved first by β-secretase (β) and subsequently by γ-secretase (γ) to generate the pathological Aβ fragments that accumulate in brains of individuals with AD.

References

    1. Aqul A., Liu B., Ramirez C. M., Pieper A. A., Estill S. J., Burns D. K., Liu B., Repa J. J., Turley S. D., Dietschy J. M. (2011). Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci. 31, 9404–9413
    1. Bales K. R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J. C., Sullivan P. M., Paul S. M. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771–6779
    1. Bar-On P., Crews L., Koob A. O., Mizuno H., Adame A., Spencer B., Masliah E. (2008). Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson’s disease. J. Neurochem. 105, 1656–1667
    1. Barrett P. J., Song Y., Van Horn W. D., Hustedt E. J., Schafer J. M., Hadziselimovic A., Beel A. J., Sanders C. R. (2012). The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168–1171
    1. Baudry M., Yao Y., Simmons D., Liu J., Bi X. (2003). Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol. 184, 887–903
    1. Beffert U., Stolt P. C., Herz J. (2004). Functions of lipoprotein receptors in neurons. J. Lipid Res. 45, 403–409
    1. Bien-Ly N., Gillespie A. K., Walker D., Yoon S. Y., Huang Y. (2012). Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32, 4803–4811
    1. Björkhem I., Hansson M. (2010). Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46–49
    1. Björkhem I., Heverin M., Leoni V., Meaney S., Diczfalusy U. (2006). Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. Suppl. 114, 43–49
    1. Björkhem I., Lövgren-Sandblom A., Piehl F., Khademi M., Pettersson H., Leoni V., Olsson T., Diczfalusy U. (2011). High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction? J. Lipid Res. 52, 170–174
    1. Björnsson O. G., Sparks J. D., Sparks C. E., Gibbons G. F. (1994). Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. Eur. J. Clin. Invest. 24, 137–148
    1. Bodovitz S., Klein W. L. (1996). Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436–4440
    1. Bosco D. A., Fowler D. M., Zhang Q., Nieva J., Powers E. T., Wentworth P., Jr, Lerner R. A., Kelly J. W. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat. Chem. Biol. 2, 249–253
    1. Boyles J. K., Pitas R. E., Wilson E., Mahley R. W., Taylor J. M. (1985). Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76, 1501–1513
    1. Boyles J. K., Zoellner C. D., Anderson L. J., Kosik L. M., Pitas R. E., Weisgraber K. H., Hui D. Y., Mahley R. W., Gebicke-Haerter P. J., Ignatius M. J., et al. (1989). A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 83, 1015–1031
    1. Brown M. S., Goldstein J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47
    1. Bryleva E. Y., Rogers M. A., Chang C. C., Buen F., Harris B. T., Rousselet E., Seidah N. G., Oddo S., LaFerla F. M., Spencer T. A., et al. (2010). ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. USA 107, 3081–3086
    1. Bu G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344
    1. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Mathews P. M., Noble W., Matsuoka Y., Duff K. (2003). Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 23, 5645–5649
    1. Castellano J. M., Kim J., Stewart F. R., Jiang H., DeMattos R. B., Patterson B. W., Fagan A. M., Morris J. C., Mawuenyega K. G., Cruchaga C., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89
    1. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923
    1. Corder E. H., Saunders A. M., Risch N. J., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Jr, Rimmler J. B., Locke P. A., Conneally P. M., Schmader K. E., et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180–184
    1. Cramer P. E., Cirrito J. R., Wesson D. W., Lee C. Y., Karlo J. C., Zinn A. E., Casali B. T., Restivo J. L., Goebel W. D., James M. J., et al. (2012). ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506
    1. Crews L., Mizuno H., Desplats P., Rockenstein E., Adame A., Patrick C., Winner B., Winkler J., Masliah E. (2008). Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J. Neurosci. 28, 4250–4260
    1. de Lau L. M., Koudstaal P. J., Hofman A., Breteler M. M. (2006). Serum cholesterol levels and the risk of Parkinson’s disease. Am. J. Epidemiol. 164, 998–1002
    1. Dietschy J. M., Turley S. D. (2001). Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105–112
    1. Dietschy J. M., Turley S. D. (2004). Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375–1397
    1. Distl R., Treiber-Held S., Albert F., Meske V., Harzer K., Ohm T. G. (2003). Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J. Pathol. 200, 104–111
    1. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. (2003). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113–123
    1. Elder G. A., Cho J. Y., English D. F., Franciosi S., Schmeidler J., Sosa M. A., Gasperi R. D., Fisher E. A., Mathews P. M., Haroutunian V., et al. (2007). Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J. Neurochem. 102, 1220–1231
    1. Fagan A. M., Murphy B. A., Patel S. N., Kilbridge J. F., Mobley W. C., Bu G., Holtzman D. M. (1998). Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (−/−) mice but impaired clearance of axonal degeneration products following injury. Exp. Neurol. 151, 314–325
    1. Fantini J., Carlus D., Yahi N. (2011). The fusogenic tilted peptide (67–78) of α-synuclein is a cholesterol binding domain. Biochim. Biophys. Acta 1808, 2343–2351
    1. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K., et al. (2002). Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59, 1257–1258
    1. Fryer J. D., Demattos R. B., McCormick L. M., O’Dell M. A., Spinner M. L., Bales K. R., Paul S. M., Sullivan P. M., Parsadanian M., Bu G., et al. (2005). The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280, 25754–25759
    1. Grimm M. O., Rothhaar T. L., Hartmann T. (2012). The role of APP proteolytic processing in lipid metabolism. Exp. Brain Res. 217, 365–375
    1. Gupta V. B., Laws S. M., Villemagne V. L., Ames D., Bush A. I., Ellis K. A., Lui J. K., Masters C., Rowe C. C., Szoeke C., et al. (2011). Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091–1098
    1. Hawes C. M., Wiemer H., Krueger S. R., Karten B. (2010). Pre-synaptic defects of NPC1-deficient hippocampal neurons are not directly related to plasma membrane cholesterol. J. Neurochem. 114, 311–322
    1. Hayashi H., Campenot R. B., Vance D. E., Vance J. E. (2004). Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J. Biol. Chem. 279, 14009–14015
    1. Hayashi H., Campenot R. B., Vance D. E., Vance J. E. (2009). Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin. J. Biol. Chem. 284, 29605–29613
    1. Hayashi H. H., Campenot R. B., Vance D. E., Vance J. E. (2007). Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J. Neurosci. 27, 1933–1941
    1. Herz J. (2001a). Lipoprotein receptors: beacons to neurons? Trends Neurosci. 24, 193–195
    1. Herz J. (2001b). The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29, 571–581
    1. Hirsch-Reinshagen V., Wellington C. L. (2007). Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer’s disease. Curr. Opin. Lipidol. 18, 325–332
    1. Hirsch-Reinshagen V., Zhou S., Burgess B. L., Bernier L., McIsaac S. A., Chan J. Y., Tansley G. H., Cohn J. S., Hayden M. R., Wellington C. L. (2004). Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279, 41197–41207
    1. Hirsch-Reinshagen V., Maia L. F., Burgess B. L., Blain J. F., Naus K. E., McIsaac S. A., Parkinson P. F., Chan J. Y., Tansley G. H., Hayden M. R., et al. (2005). The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280, 43243–43256
    1. Hu G., Antikainen R., Jousilahti P., Kivipelto M., Tuomilehto J. (2008). Total cholesterol and the risk of Parkinson disease. Neurology 70, 1972–1979
    1. Huang X., Chen H., Miller W. C., Mailman R. B., Woodard J. L., Chen P. C., Xiang D., Murrow R. W., Wang Y. Z., Poole C. (2007). Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov. Disord. 22, 377–381
    1. Hudry E., Van Dam D., Kulik W., De Deyn P. P., Stet F. S., Ahouansou O., Benraiss A., Delacourte A., Bougnères P., Aubourg P., et al. (2010). Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol. Ther. 18, 44–53
    1. Ignatius M. J., Gebicke-Härter P. J., Skene J. H., Schilling J. W., Weisgraber K. H., Mahley R. W., Shooter E. M. (1986). Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. USA 83, 1125–1129
    1. Jiang X., Sidhu R., Porter F. D., Yanjanin N. M., Speak A. O., te Vruchte D. T., Platt F. M., Fujiwara H., Scherrer D. E., Zhang J., et al. (2011). A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J. Lipid Res. 52, 1435–1445
    1. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A. (2000). Statins and the risk of dementia. Lancet 356, 1627–1631
    1. Karasinska J. M., Hayden M. R. (2011). Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 7, 561–572
    1. Karten B., Vance D. E., Campenot R. B., Vance J. E. (2002). Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J. Neurochem. 83, 1154–1163
    1. Karten B., Vance D. E., Campenot R. B., Vance J. E. (2003). Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J. Biol. Chem. 278, 4168–4175
    1. Karten B., Hayashi H., Francis G. A., Campenot R. B., Vance D. E., Vance J. E. (2005). Generation and function of astroglial lipoproteins from Niemann-Pick type C1-deficient mice. Biochem. J. 387, 779–788
    1. Karten B., Campenot R. B., Vance D. E., Vance J. E. (2006). The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals. J. Lipid Res. 47, 504–514
    1. Kim J., Castellano J. M., Jiang H., Basak J. M., Parsadanian M., Pham V., Mason S. M., Paul S. M., Holtzman D. M. (2009). Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632–644
    1. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10, 719–726
    1. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha–secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98, 5815–5820
    1. Lee C. Y., Tse W., Smith J. D., Landreth G. E. (2012). Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 287, 2032–2044
    1. Leoni V., Caccia C. (2011). Oxysterols as biomarkers in neurodegenerative diseases. Chem. Phys. Lipids 164, 515–524
    1. Leoni V., Solomon A., Kivipelto M. (2010). Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment. Biochem. Soc. Trans. 38, 1021–1025
    1. Liscum L., Ruggiero R. M., Faust J. R. (1989). The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J. Cell Biol. 108, 1625–1636
    1. Liu B., Turley S. D., Burns D. K., Miller A. M., Repa J. J., Dietschy J. M. (2009). Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. Proc. Natl. Acad. Sci. USA 106, 2377–2382
    1. Longenberger J., Shah Z. A. (2011). Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer’s disease. Curr. Alzheimer Res. 8, 434–442
    1. Lopez M. E., Klein A. D., Dimbil U. J., Scott M. P. (2011). Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder. J. Neurosci. 31, 4367–4378
    1. Mailman T., Hariharan M., Karten B. (2011). Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J. Neurochem. 119, 1002–1015
    1. Maity T., Fuse N., Beachy P. A. (2005). Molecular mechanisms of Sonic hedgehog mutant effects in holoprosencephaly. PNAS 102, 17026–17031
    1. Mann R. K., Beachy P. A. (2000). Cholesterol modification of proteins. Biochim. Biophys. Acta 1529, 188–202
    1. Marwarha G., Rhen T., Schommer T., Ghribi O. (2011). The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors – relevance to Parkinson’s disease. J. Neurochem. 119, 1119–1136
    1. Masliah E., Mallory M., Ge N., Alford M., Veinbergs I., Roses A. D. (1995). Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136, 107–122
    1. Mauch D. H., Nägler K., Schumacher S., Göritz C., Müller E. C., Otto A., Pfrieger F. W. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357
    1. Michikawa M., Fan Q. W., Isobe I., Yanagisawa K. (2000). Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74, 1008–1016
    1. Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., Pitas R. E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850–852
    1. Nieweg K., Schaller H., Pfrieger F. W. (2009). Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109, 125–134
    1. Oitzl M. S., Mulder M., Lucassen P. J., Havekes L. M., Grootendorst J., de Kloet E. R. (1997). Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res. 752, 189–196
    1. Peake K. B., Vance J. E. (2012). Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. J. Biol. Chem. 287, 9290–9298
    1. Peake K. B., Campenot R. B., Vance D. E., Vance J. E. (2011). Niemann-Pick Type C1 deficiency in microglia does not cause neuron death in vitro. Biochim. Biophys. Acta 1812, 1121–1129
    1. Popko B., Goodrum J. F., Bouldin T. W., Zhang S. H., Maeda N. (1993). Nerve regeneration occurs in the absence of apolipoprotein E in mice. J. Neurochem. 60, 1155–1158
    1. Porter F. D. (2006). Cholesterol precursors and facial clefting. J. Clin. Invest. 116, 2322–2325
    1. Porter F. D., Herman G. E. (2011). Malformation syndromes caused by disorders of cholesterol synthesis. J. Lipid Res. 52, 6–34
    1. Porter J. A., Young K. E., Beachy P. A. (1996). Cholesterol modification of hedgehog signaling proteins in animal development. Science 274, 255–259
    1. Posse de Chaves E. I., Rusiñol A. E., Vance D. E., Campenot R. B., Vance J. E. (1997). Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J. Biol. Chem. 272, 30766–30773
    1. Posse de Chaves E. I., Vance D. E., Campenot R. B., Kiss R. S., Vance J. E. (2000). Uptake of lipoproteins for axonal growth of sympathetic neurons. J. Biol. Chem. 275, 19883–19890
    1. Quan G., Xie C., Dietschy J. M., Turley S. D. (2003). Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res. Dev. Brain Res. 146, 87–98
    1. Radhakrishnan A., Goldstein J. L., McDonald J. G., Brown M. S. (2008). Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 8, 512–521
    1. Rantham Prabhakara J. P., Feist G., Thomasson S., Thompson A., Schommer E., Ghribi O. (2008). Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. J. Neurochem. 107, 1722–1729
    1. Reiner A., Albin R. L., Anderson K. D., D’Amato C. J., Penney J. B., Young A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 85, 5733–5737
    1. Rigamonti D., Bauer J. H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M. R., Li Y., et al. (2000). Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20, 3705–3713
    1. Rosenbaum A. I., Zhang G., Warren J. D., Maxfield F. R. (2010). Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc. Natl. Acad. Sci. USA 107, 5477–5482
    1. Roy A., Pahan K. (2011). Prospects of statins in Parkinson disease. Neuroscientist 17, 244–255
    1. Russell D. W., Halford R. W., Ramirez D. M., Shah R., Kotti T. (2009). Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 78, 1017–1040
    1. Sanan D. A., Weisgraber K. H., Russell S. J., Mahley R. W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A. D., et al. (1994). Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94, 860–869
    1. Sano M., Bell K. L., Galasko D., Galvin J. E., Thomas R. G., van Dyck C. H., Aisen P. S. (2011). A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556–563
    1. Sarna J. R., Larouche M., Marzban H., Sillitoe R. V., Rancourt D. E., Hawkes R. (2003). Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J. Comp. Neurol. 456, 279–291
    1. Selkoe D. J. (2001). Clearing the brain’s amyloid cobwebs. Neuron 32, 177–180
    1. Selkoe D. J. (2002). Alzheimer’s disease is a synaptic failure. Science 298, 789–791
    1. Shafaati M., Marutle A., Pettersson H., Lövgren-Sandblom A., Olin M., Pikuleva I., Winblad B., Nordberg A., Björkhem I. (2011). Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation. J. Lipid Res. 52, 1004–1010
    1. Shepardson N. E., Shankar G. M., Selkoe D. J. (2011a). Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68, 1239–1244
    1. Shepardson N. E., Shankar G. M., Selkoe D. J. (2011b). Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 68, 1385–1392
    1. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G., Simons K. (1998). Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460–6464
    1. Smith D. W., Lemli L., Opitz J. M. (1964). A newly recognized syndrome of multiple congenital anomalies. J. Pediatr. 64, 210–217
    1. Sparks D. L., Scheff S. W., Hunsaker J. C., 3rd, Liu H., Landers T., Gross D. R. (1994). Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94
    1. Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L.-M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., Roses A. D. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098–8102
    1. Tan J., Evin G. (2012). B-site APP-cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis. J. Neurochem. 120, 869–880
    1. Ujiie M., Dickstein D. L., Carlow D. A., Jefferies W. A. (2003). Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463–470
    1. Umeda T., Tomiyama T., Kitajima E., Idomoto T., Nomura S., Lambert M. P., Klein W. L., Mori H. (2012). Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer’s disease model mice. Life Sci .(in press).
    1. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., et al. (2005). Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J. Neurosci. 25, 9932–9939
    1. Valenza M., Leoni V., Karasinska J. M., Petricca L., Fan J., Carroll J., Pouladi M. A., Fossale E., Nguyen H. P., Riess O., et al. (2010). Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J. Neurosci. 30, 10844–10850
    1. Vance J. E. (2010). Transfer of cholesterol by the NPC team. Cell Metab. 12, 105–106
    1. Vance J. E., Hayashi H. (2010). Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim. Biophys. Acta 1801, 806–818
    1. Vanier M. T., Millat G. (2003). Niemann-Pick disease type C. Clin. Genet. 64, 269–281
    1. Vaughan C. J., Gotto A. M., Jr (2004). Update on statins: 2003. Circulation 110, 886–892
    1. Veinbergs I., Jung M. W., Young S. J., Van Uden E., Groves P. M., Masliah E. (1998). Altered long-term potentiation in the hippocampus of apolipoprotein E-deficient mice. Neurosci. Lett. 249, 71–74
    1. Wahrle S. E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J. D., Kowalewski T., Holtzman D. M. (2004). ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987–40993
    1. Wahrle S. E., Jiang H., Parsadanian M., Hartman R. E., Bales K. R., Paul S. M., Holtzman D. M. (2005). Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236–43242
    1. Wahrle S. E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C. L., Bales K. R., et al. (2008). Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671–682
    1. Wang M. L., Motamed M., Infante R. E., Abi-Mosleh L., Kwon H. J., Brown M. S., Goldstein J. L. (2010). Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes. Cell Metab. 12, 166–173
    1. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443
    1. Xue Y., Lee S., Ha Y. (2011). Crystal structure of amyloid precursor-like protein 1 and heparin complex suggests a dual role of heparin in E2 dimerization. Proc. Natl. Acad. Sci. USA 108, 16229–16234
    1. Yu T., Shakkottai V. G., Chung C., Lieberman A. P. (2011). Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration. Hum. Mol. Genet. 20, 4440–4451

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi